Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
Authors:
- Simona De GregoriSGSimona De Gregori
- Eleonora GelliEGEleonora Gelli
- Mara CaponeMCMara Capone
- Giulia GambiniGGGiulia Gambini
- Elisa RoncoroniERElisa Roncoroni
- Marianna RossiMRMarianna Rossi
- Claudia Patricia Tobar CabreraCCClaudia Patricia Tobar Cabrera
- Gianluca MartiniGMGianluca Martini
- Ludovica CalabrettaLCLudovica Calabretta
- Luca ArcainiLALuca Arcaini
- Riccardo AlbertiniRARiccardo Albertini
- Patrizia ZappasodiPZPatrizia Zappasodi
Open Access
- 8 June 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (6) , 1680
Abstract
The Food and Drug Administration currently approves the combination of hypomethylating agents (HMA), azacytidine or decitabine with venetoclax (VEN) for acute myeloid leukemia (AML) patients aged more than 75 years and for patients unsuitable for intensive chemotherapy. The risk of fungal infection in the early phase of treatment is not negligible; therefore, posaconazole (PCZ) is commonly administered as primary prophylaxis. A drug–drug interaction between VEN and PCZ is well known, but the trend of serum levels of venetoclax when both drugs are overlapped is not clear. In total, 165 plasma samples from 11 elderly AML patients receiving combined treatment with HMA, VEN and PCZ were analyzed by a validated analytical method (high-pressure liquid chromatography–tandem mass spectrometry). Venetoclax trough plasma concentrations were detected during the 3 days of ramp-up as well as on day 7 and day 12 of treatment when the exposure as the area under the plasma concentration–time curve and the accumulation ratio were also calculated. The results were compared with the expected data for 400 mg/dose VEN administered alone—the confirmed high inter-individual variability in pharmacokinetics suggests the need for therapeutic drug monitoring.Keywords
Funding Information
- Fondazione IRCCS Policlinico San Matteo, Pavia Institutional Review Board Statement
This publication has 20 references indexed in Scilit:
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blastsBlood, 2015
- Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemiaNature Medicine, 2015
- Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid LeukemiaCancer Discovery, 2014
- BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignanciesLeukemia, 2014
- World Medical Association Declaration of HelsinkiJAMA, 2013
- BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem CellsCell Stem Cell, 2013
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid LeukemiaJournal of Clinical Oncology, 2012
- Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered AgentsClinical Infectious Diseases, 2009
- Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with NeutropeniaNew England Journal of Medicine, 2007
- BCL-2 FAMILY: Regulators of Cell DeathAnnual Review of Immunology, 1998